Akums Drugs and Pharmaceutical - Asset Resilience Ratio

Latest as of September 2025: 28.08%

Akums Drugs and Pharmaceutical (AKUMS) has an Asset Resilience Ratio of 28.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs14.49 Billion
≈ $156.67 Million USD Cash + Short-term Investments

Total Assets

Rs51.59 Billion
≈ $557.96 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Akums Drugs and Pharmaceutical's Asset Resilience Ratio has changed over time. See financial flexibility index of Akums Drugs and Pharmaceutical to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Akums Drugs and Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Akums Drugs and Pharmaceutical.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs14.49 Billion 28.08%
Total Liquid Assets Rs14.49 Billion 28.08%

Asset Resilience Insights

  • Very High Liquidity: Akums Drugs and Pharmaceutical maintains exceptional liquid asset reserves at 28.08% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Akums Drugs and Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Akums Drugs and Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
Drug Manufacturers - Specialty & Generic 2.04%
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
Drug Manufacturers - Specialty & Generic 0.01%
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
Drug Manufacturers - Specialty & Generic 7.85%
Jw Pharmac
KO:001060
Drug Manufacturers - Specialty & Generic 3.65%
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Samjin Pharm
KO:005500
Drug Manufacturers - Specialty & Generic 0.25%

Annual Asset Resilience Ratio for Akums Drugs and Pharmaceutical (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Akums Drugs and Pharmaceutical.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 11.69% Rs4.81 Billion
≈ $51.99 Million
Rs41.13 Billion
≈ $444.85 Million
+6.66pp
2024-03-31 5.03% Rs1.77 Billion
≈ $19.12 Million
Rs35.16 Billion
≈ $380.28 Million
+2.00pp
2023-03-31 3.03% Rs988.92 Million
≈ $10.69 Million
Rs32.67 Billion
≈ $353.26 Million
+1.46pp
2022-03-31 1.57% Rs481.56 Million
≈ $5.21 Million
Rs30.69 Billion
≈ $331.91 Million
--
pp = percentage points

About Akums Drugs and Pharmaceutical

NSE:AKUMS India Drug Manufacturers - Specialty & Generic
Market Cap
$1.13 Billion
Rs104.29 Billion INR
Market Cap Rank
#8290 Global
#417 in India
Share Price
Rs681.20
Change (1 day)
+3.47%
52-Week Range
Rs414.05 - Rs701.95
All Time High
Rs1119.95
About

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and co… Read more